[HTML][HTML] Inflammation, fibrosis and cancer: mechanisms, therapeutic options and challenges

B Wu, QH Sodji, AK Oyelere - Cancers, 2022 - mdpi.com
Simple Summary Inflammation is like the proverbial double-edged sword. Controlled short-
term inflammation could be a protective response while uncontrolled inflammation sustains …

Targeting cancer epigenetic pathways with small-molecule compounds: therapeutic efficacy and combination therapies

Y Wang, Q Xie, H Tan, M Liao, S Zhu, LL Zheng… - Pharmacological …, 2021 - Elsevier
Epigenetics mainly refers to covalent modifications to DNA or histones without affecting
genomes, which ultimately lead to phenotypic changes in cells or organisms. Given the …

[HTML][HTML] Roles and regulation of histone acetylation in hepatocellular carcinoma

J Xia, X Qin, L Zhang, S Liu, X Shi, H Ren - Frontiers in Genetics, 2022 - frontiersin.org
Hepatocellular Carcinoma (HCC) is the most frequent malignant tumor of the liver, but its
prognosis is poor. Histone acetylation is an important epigenetic regulatory mode that …

[HTML][HTML] Deciphering a mitochondria-related signature to supervise prognosis and immunotherapy in hepatocellular carcinoma

Y Shi, G Huang, F Jiang, J Zhu, Q Xu, H Fang… - Frontiers in …, 2022 - frontiersin.org
Background Hepatocellular carcinoma (HCC) is a major public health problem in humans.
The imbalance of mitochondrial function has been discovered to be closely related to the …

Synthetic methodology-enabled discovery of a tunable indole template for COX-1 inhibition and anti-cancer activity

GG Faura, B Wu, AK Oyelere, S France - Bioorganic & Medicinal Chemistry, 2022 - Elsevier
Establishing structure–activity relationships (SAR) for privileged pharmacophores, such as
the indole scaffold, is a key step in the early stages of drug discovery. Herein, we report the …

Emerging therapeutic strategies in cancer therapy by HDAC inhibition as the chemotherapeutic potent and epigenetic regulator

D Karati, S Mukherjee, S Roy - Medical Oncology, 2024 - Springer
In developing new cancer medications, attention has been focused on novel epigenetic
medicines called histone deacetylase (HDAC) inhibitors. Our understanding of cancer …

[HTML][HTML] Glutathione peroxidase 8 suppression by histone deacetylase inhibitors enhances endoplasmic reticulum stress and cell death by oxidative stress in …

HA Lee, KB Chu, EK Moon, FS Quan - Antioxidants, 2021 - mdpi.com
Histone deacetylase inhibitors (HDACi) are emerging as anti-hepatocellular carcinoma
(HCC) agents. However, the molecular mechanisms underlying HDACi-induced …

[PDF][PDF] Inflammation, Fibrosis and Cancer: Mechanisms, Therapeutic Options and Challenges. Cancers 2022, 14, 552

B Wu, QH Sodji, AK Oyelere - 2022 - researchgate.net
Uncontrolled inflammation is a salient factor in multiple chronic inflammatory diseases and
cancers. In this review, we provided an in-depth analysis of the relationships and distinctions …

蛋白质翻译后修饰在皮肤鳞状细胞癌中的功能研究进展.

杨润, 乔佳月, 王铎蓉, 谭千桦… - Journal of Modern …, 2024 - search.ebscohost.com
杨润1 综述, 乔佳月1, 王铎蓉1, 谭千桦2, 刘欢3, 王琳2△ 审校(1. 西安医学院第一临床医学院,
陕西西安710021; 2. 西安医学院医学技术学院, 陕西西安710021; 3. 西安医学院基础与转化医学 …

A Novel Liver Cancer-Selective Histone Deacetylase Inhibitor Is Effective Against Hepatocellular Carcinoma and Induces Durable Responses with Immunotherapy

B Wu, S Tapadar, Z Ruan, CQ Sun, RS Arnold… - bioRxiv, 2024 - biorxiv.org
Hepatocellular cancer (HCC) progression is facilitated by gene-silencing chromatin histone
hypoacetylation due to histone deacetylases (HDACs) activation. However, inhibiting …